MEDICILON

contact us krjpencn

뉴스현황

Press Events

현재 위치: > 뉴스현황 > Press Events > Ligand Binding Assay

Ligand Binding Assay

저자:   업로드:2017-06-06  조회수:

There are numerous types of ligand binding assays, both radioactive and non-radioactive.  As such, ligand binding assays are a superset of radio-binding assays, which are the conceptual inverse of radioimmunoassays (RIA). Some newer types are called "mix-and-measure" assays because they do not require separation of bound ligands.



Ligand binding assays are used primarily in pharmacology for various demands. Specifically, despite the human body’s endogenous receptors, hormones and other neurotransmitters, pharmacologists utilize assays in order to create drugs that are selective or mimic, the endogenously found cellular components.  On the other hand, such techniques are also available to create receptor antagonists in order to prevent further cascades.  Such advances provide researchers with the ability not only to quantify hormones and hormone receptors, but also to contribute important pharmacological information in drug development and treatment plans.


Our Services Comprise:

- Assay Development and Validation
- Customizing de novo ELISA Kits in Different Formats
- Development of Immunogenicity Assays for Therapeutic Proteins, Monoclonal Antibodies or Polypeptides (Preclinical & Clinical)
- Method Transfer, Optimization & Development
- Quantitative ELISA Assay Development

- Single or Multiplexed Biomarkers


Medicilon has expanded its bioanalytical services and now offers ligand binding assays (LBA) for macromolecular drug therapeutics, immunogenicity screening, and biomarkers in biological matrices.  Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assay (ELISA)-based applications are the primary tools for these services.

The Ligand Binding Assay

A ligand is a substance that binds with a target biomolecule. In the Good Laboratory Practice (GLP) facility, a ligand serves as a signal triggering molecule that binds to a protein, revealing specific test results. Various ligand binding assay applications may utilize ligands that are substrates, inhibitors, activators, or neurotransmitters. Their binding property, or the strength of the bond formed, is called its affinity.


A ligand binding assay, carried out under the strict standards of Good Laboratory Practice (GLP), can determine the binding affinity between a ligand and its receptor molecule. The strength of the affinity becomes relevant when the energy created by a high affinity ligand bond can be directed toward causing a change in reception conformation, which alters the behavior of an associated enzyme.


A ligand that behaves in this way, changing its receptor and triggering a behavioral response, is called an agonist. By helping researchers to determine the level of affinity between a ligand and its receptor, a Good Laboratory Practice (GLP) compliant ligand binding assay reveals the optimum concentration of the agonist for triggering the intended physiological response, thus providing data important to determining dosages of microRNA drugs.


A ligand binding assay can also determine ligand efficacy -- the biological effect and the magnitude of the effect when the ligand binds to its receptor. Efficacy is another critical factor in dosage determination. Only a Good Laboratory Practice (GLP) compliant CRO, such as Accelerō® Bioanalytics, is fully qualified to perform a ligand binding assay that provides the most accurate, reproducible, and meticulously tracked results.


By carrying out ligand binding assay support in an FDA certified, Good Lab

이전:Everyday Chemicals May Cause Cancer by Disrupting DNA Repair

다음에:Tea Consumption Leads to Epigenetic Changes in Women